−0.87USD
−28.04 MUSD
64.23 MUSD
30.76 M
About HLS Therapeutics Inc.
Sector
CEO
Craig Millian
Headquarters
Etobicoke
Website
Employees (FY)
91
Founded
2014
FIGI
BBG000GY50Y4
HLS Therapeutics, Inc.e ngages in commercializing pharmaceutical products. It specializes in central nervous system and cardiovascular markets. The company was founded by Gregory Gubitz and Gilbert Godin on June 5, 2014 and is headquartered in Etobicoke, Canada.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HLTRF is 3.56 USD — it has decreased by 7.53% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange HLS Therapeutics Inc. stocks are traded under the ticker HLTRF.
HLS Therapeutics Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
HLTRF stock is 8.15% volatile and has beta coefficient of 0.10. Check out the list of the most volatile stocks — is HLS Therapeutics Inc. there?
HLTRF earnings for the last quarter are −0.21 USD per share, whereas the estimation was −0.11 USD resulting in a −96.74% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about HLS Therapeutics Inc. earnings.
HLS Therapeutics Inc. revenue for the last quarter amounts to 16.04 M USD despite the estimated figure of 16.44 M USD. In the next quarter revenue is expected to reach 16.00 M USD.
Yes, you can track HLS Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
HLTRF stock has fallen by 7.53% compared to the previous week, the month change is a 14.16% rise, over the last year HLS Therapeutics Inc. has showed a 20.36% decrease.
HLTRF net income for the last quarter is −5.55 M USD, while the quarter before that showed −6.81 M USD of net income which accounts for 18.54% change. Track more HLS Therapeutics Inc. financial stats to get the full picture.
Today HLS Therapeutics Inc. has the market capitalization of 110.62 M, it has decreased by 1.93% over the last week.
Yes, HLTRF dividends are paid quarterly. The last dividend per share was 0.04 USD. As of today, Dividend Yield (TTM)% is 4.21%. Tracking HLS Therapeutics Inc. dividends might help you take more informed decisions.
Like other stocks, HLTRF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HLS Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 91.00 employees. See our rating of the largest employees — is HLS Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HLS Therapeutics Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HLS Therapeutics Inc. stock shows the sell signal. See more of HLS Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HLS Therapeutics Inc. future price: according to them, HLTRF price has a max estimate of 7.77 USD and a min estimate of 3.07 USD. Read a more detailed HLS Therapeutics Inc. forecast: see what analysts think of HLS Therapeutics Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HLS Therapeutics Inc. EBITDA is 21.99 M USD, and current EBITDA margin is 34.23%. See more stats in HLS Therapeutics Inc. financial statements.